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The human immunodeficiency virus type-1 (HIV-1) genome containsmultiple, highly conserved structural
RNA domains that play key roles in essential viral processes. Interference with the function of these RNA
domains either by disrupting their structures or by blocking their interaction with viral or cellular factors
may seriously compromise HIV-1 viability. RNA aptamers are amongst the most promising synthetic
molecules able to interact with structural domains of viral genomes. However, aptamer shortening up to
their minimal active domain is usually necessary for scaling up production, what requires very
time-consuming, trial-and-error approaches. Here we report on the in vitro selection of 64 nt-long specific
aptamers against the complete 59-untranslated region of HIV-1 genome, which inhibit more than 75% of
HIV-1 production in a human cell line. The analysis of the selected sequences and structures allowed for the
identification of a highly conserved 16 nt-long stem-loop motif containing a common 8 nt-long apical loop.
Based on this result, an in silico designed 16 nt-long RNA aptamer, termed RNApt16, was synthesized, with
sequence 59-CCCCGGCAAGGAGGGG-39. TheHIV-1 inhibition efficiency of such an aptamer was close to
85%, thus constituting the shortest RNA molecule so far described that efficiently interferes with HIV-1
replication.
T
he human immunodeficiency virus type 1 (HIV-1) genome is a 9.2 kb long, single-stranded RNA (ssRNA)
molecule of positive polarity with multiple open reading frames (ORFs), including those for structural and
functional proteins gag, pol and env. The coding region is flanked at both ends by untranslated regions
(UTR). HIV-1 infective particles contain two identical genomic RNA molecules. The genome is reverse tran-
scribed into a cDNA copy that is integrated into the host genome. The transcription of the proviral cDNA
generates capped, full-length genomic RNAs thatmust undergo alternative splicing to accommodate the different
ORFs immediately downstream of the capped 59-end. All the HIV-1 genomic and subgenomic RNAs share
approximately the first 300 nt of their 59-UTR. This sequence contains several well-characterized and conserved
functional RNAdomains1,2 including the trans-activator response (TAR) element3, the polyadenylation [poly(A)]
region4, the primer-binding site (PBS)5, the dimerisation initiation site (DIS)6, themajor splicing donor (SD)7 and
part of the packaging signal (psi)8 (Fig. 1). These RNA domains are involved in alternative, functionally relevant
RNA-RNA interactions that determine two mutually exclusive conformations of the overall 59-UTR region,
termed Branched Multiple Hairpins (BMH) and Long Distance Interaction (LDI)9.
The identification of highly conserved structural-functional elements within viral RNA genomes has attracted
much attention due to their potential use as targets for novel antiviral drugs. Indeed, small RNA molecules have
been proved to be efficient inhibitors targeting functional RNA genomic domains (including those at the 59-UTR)
as well as genetic products of HIV-110–15.Some of the inhibitory RNAs have been included in clinical trials for
HIV-1 treatment16. This strategy has been also applied to other clinically relevant RNA viruses17–20.
Aptamers are short RNAorDNAoligonucleotides that, due to their three dimensional structure, can efficiently
and specifically bind a molecular target21. Most of the developed aptamers have been artificially obtained using
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SELEX (Systematic Evolution of Ligands by EXponential enrich-
ment) techniques22, and their potential as therapeutic agents has
been widely established23–25. A SELEX procedure consists in the
exposition of a random population of nucleic acid molecules to a
desired target, in experimental conditions that enable the segregation
of the molecules bound to the target for a subsequent amplification
round. The successive selection-amplification cycles progressively
enrich the population in molecules able to bind the target. Usually,
the starting population for SELEX consists of molecules with a ran-
dom sequence flanked by constant regions needed for primer bind-
ing. This fact imposes a minimal aptamer length, limiting in turn its
usefulness as a therapeutic agent. Several deletionmethods have been
developed to experimentally obtain the minimal domain that allows
efficient aptamer binding12,26,27. Bioinformatic strategies constitute
an alternative, though less explored approach for this purpose28–30.
An example of such a ‘rational truncation approach’ has been suc-
cessfully applied to the production of 40–50 nt long functional RNA
aptamers31. We report here the in vitro selection of efficient anti-
HIV-1 RNA aptamers targeting the viral 59UTR, and their short-
ening to a 16 nt-long minimal aptamer by the application of compu-
tational strategies based on sequence and structure analysis to
identify and improve core aptamer domains. The combination of
an in vitro selection with the in silico approach has allowed us to
design the shortest reported RNA molecule that efficiently inhibits
HIV-1 production in a human cell line.
Results
In vitro selection of RNA aptamers against the 59-UTR of HIV-1.
An in vitro selection strategy was used to isolate anti-HIV-1 RNA
aptamers targeting the first 308 nt of the 59-UTR of the HIV-1
subtype B NL4.3 genome. This target corresponds to the sequence
fragment of the 59UTR that is common to all genomic and
subgenomic HIV-1 RNAs2, including 8 nt from the unspliced SD
domain that have been maintained in the molecule to prevent
alternative foldings of the entire molecule due to SD partial
Figure 1 | Schematic representation of the BMH conformation of the HIV-1 UTR308. Essential structural domains are indicated. Putative binding sites
for RNApt16 (boxed) and the in vitro selected aptamers are shown in boldface, and labelled from (a) to (f). The alternative, partially overlapping binding
region (a9) is shown.
www.nature.com/scientificreports
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deletion after splicing. The starting RNA population consisted of
roughly 7 3 1015 variants of 64 nt long molecules. RNA molecules
were binding-challenged against the target molecule fixed to a
sepharose-streptavidin column. Fourteen cycles of selection-
amplification were performed, and the selective pressure was
stepwise modified by increasing the binding temperature from
round IV on, and by reducing the target:aptamer ratio from round
XI on. The yield of complex formation increased along the selection
process, as shown by the evolution of Bmax32 (Fig. 2). A total of 299
individual clonal sequences derived from the populations selected at
rounds 0 (initial random population, 30 seqs), I (30), III (31), V (24),
VIII (28), IX (32), X (35), XI (52) and XIV (37) were analyzed (Fig. 3
and data not shown). The presence of intra- and/or inter-round
repeated sequences supposed a reduction in the diversity of the
analyzed collection to 216 different molecules (Table S1). The
repeated sequences gained representation from round IX on, thus
showing that the selection process was effective. Finally, 188 out of
the 216 different sequences showed the expected length of 64 nt,
while the others contained deletions of one or more nucleotides in
their variable region. The clustering of those 188 different, 64 nt-long
sequences, is shown in Figure S1.
Sequence analysis showed that three clonal sequences from round
IX (9.4% of the population), 15 from roundX (42.9%), 35 from round
XI (67.3%), and 33 from XIV (89.2%) shared the consensus octamer
59-GGCAAGGA-39 (with a point mutation in sequence XIV32: 59-
GGCAGGGA-39). Interestingly, all main groups of repeated
sequences in rounds XI and XIV contained the consensus octamer.
Two groups were particularly relevant at rounds XI and XIV: i)
Group 1, formed by clone 21 and other 6 repeated sequences of
round XI (termed XI21-7) identical to 6 repeated sequences of round
XIV (termed XIV26-6); and ii) Group 2, constituted by 17 sequences
of round XI (termed XI1-17) identical to 23 repeated sequences of
roundXIV (termed XIV22-23). The latter groupwas first observed in
round IX (see Table S1). Thus, our results indicate that the selection
procedure has been successful in reducing the initial variability to
two major sequences that together represent the 51% and 80% of the
total population in rounds XI and XIV, respectively. Sequence com-
parison showed that the hexanucleotide 59-GGCAAG-39 within the
consensus octamer is complementary to the apical loop of the
poly(A) domain within the repeated region (R) located at both 59
and 39-UTRs of HIV-1 (Fig. 1 and 3), thus suggesting the putative
relevance of this recognition site for the selected aptamers.
The remaining sequences in rounds XI and XIV can be grouped
into two additional groups of molecules, defined by common
sequence motifs complementary to the TAR apical loop and the
SD apical loop of HIV-1 59-UTR, respectively (Fig. 3). Additionally,
certain unique sequences were identified, which did not show a clear
sequence complementarity to any domain within the target sequence
(Fig. 3).
In silico sequence and structure analysis. To study the effect of
selection along the process, we measured the similarity of the
clonal sequences within each round. The distributions of the
Hamming distance between pairs of sequences at rounds 0, I to IX,
X to XIV, and I to XIV is shown in Figure S2. Since a different
number of sequences were available for each round, the distribu-
tions are rescaled by the factor M(M-1)/2, with M being the
number of sequences per round. For rounds 0-IX, the distributions
are relatively symmetric, and peaked between 17 and 19. This value is
close to the average Hamming distance between random sequences:
25*3/4 5 18.75, where 25 is the length of the variable region and 3/4
is the probability that a nucleotide is different from other randomly
chosen nucleotide. In turn, for rounds XI-XIV the distribution
showed several peaks at varying distances, and groups of equal
(zero Hamming distance) and very similar (distances 1 and 2)
sequences were present in the pool. Note that the height of the
peak is proportional to the absolute number of repeated sequences
within a group. The comparison of the similarities among secondary
structures along the process yields qualitatively analogous results
(Figure S3). A simultaneous comparison of the similarity between
sequences and the corresponding structures is shown in Figure S4.
That representation highlights the known fact that similar sequences
can fold into significantly different minimum free energy (MFE)
structures, and vice versa, identical structures may arise from
significantly different sequences.
Regarding the secondary structures of the folded sequences, the
evolution of two thermodynamic parameters, the ensemble diversity
(ED) and the frequency of the MFE structure along the in vitro
selection process (FME), is graphically depicted in Figure S5 for
the 188 different, 64 nt-long sequences studied. Groups of sequences
were first detected at round VIII, and the process subsequently led to
the appearance of two major groups: i) Group 1, represented by the
folded sequence XIV26-6 and characterized by a low ED and high
FME; and ii) Group 2, represented by XIV22-23, showing a high ED
and low FME.
Average values of the Hamming distance between sequences as
well as the base-pair distance between structures along the process
are depicted in Figure 2, in parallel to the evolution of the extension
of the binding reaction Bmax. A trend towards lower average distance
between all pairs of sequences and structures in the population
becomes apparent from round IX to XIV. Despite the large disper-
sion of these measures, the increase in similarity among groups of
molecules is genuine, as information on the full distributions of pair
distances (Figs. S2, S3 and S4) show. Based on the base-pair distance
values, a clustering of the secondary structures corresponding to the
188 sequences is shown in Figure S6.
Design of the RNApt16 and in silico analysis of the aptamers-target
interaction. The in silico predicted MFE secondary structure model
of the aptamers selected in round XIV is depicted in Figure 4A–C.
Folding energies corresponding to each structure (in Kcal/mol) are
DG[XIV22] 5 210.80; DG[XIV1] 5 211.80; DG[XIV32] 5
210.80; DG[XIV12] 5 210.90; DG[XIV26] 5 215.70; DG[XIV5]
5 211.10; DG[XIV48] 5 29.80; DG[XIV37] 5 27.32; DG[XIV25]
5 211.50. The most abundant structures (belonging to the Groups 1
and 2 defined above) indicate that the consensus octamer 59-
GGCAAGGA-39 is always placed in an apical loop flanked by
complementary sequences that form a double stranded region of
at least 4 bp in length. The RNAfold algorithm calculates the
likelihood that any nucleotide in a sequence actually occupies the
predicted structural position by analysing how often it appears in
the structural ensemble of the analysed sequence. While some of the
Figure 2 | Changes in relevant variables along the selection process.
Average distances were computed over all possible sequence/structure
pairs at each round, and error bars show themean square deviation of each
sample. In Bmax, error bars represent the experimental error.
www.nature.com/scientificreports
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motifs present in the folded sequences have low reliability, we
observed that the consensus octamer forming a loop plus its 4 nt
flanking regions consistently shows a stem-loop configuration. Such
an RNA motif is systematically found in most structures of the
thermodynamic ensemble of sequences in round XIV (Figure 4A–
B), and does not contribute significantly to their observed ED. The
consensus sequence of that conserved motif, with structure 59-
((((........))))-39, is 59-NNDYGGCARGGARNNN-39 (sequence
alignment not shown). Based on this fact, a 16 nt-long stem-loop
RNA molecule was in silico designed as a minimal aptamer
potentially able to interact with the 59-UTR of HIV-1. This apta-
mer was termed RNApt16, and included the consensus octamer in a
loop closed by the 4 bp-long stem allowing the highest possible
thermodynamic stability of the folded molecule, thus formed by
four consecutive C-G base pairs: 59-CCCCGGCAAGGAGGGG-39.
The secondary structure of RNApt16 is shown in Figure 4D, the
folding energy associated to its MFE is 26, 50 kcal/mol, and the
frequency of this MFE within the thermodynamic ensemble is
91,82%.
We used RNAup to predict the preferred sites of interaction
between either three selected aptamers (at round XIV) or the min-
imal engineered aptamer (RNApt16) with the target RNA. An
example of the information yielded by RNAup can be seen in
Figure S7. The regions of the target molecule with the highest prob-
ability of interaction with the aptamers are listed in Table S2. Among
them, the binding site (a), placed at the poly(A) domain (Fig. 1),
shows by far the most stable interaction.
Design of the molecule RNApt16neg as a negative control. The
design of a negative control molecule to evaluate the activity of
Figure 3 | Aptamer sequences of rounds XI and XIV, grouped attending to putative common targets. The variable region is shown in boldface. The
single-stranded sequences predicted by RNAfold software59 are boxed. White text represents the sequences complementary to 59-UTR loop regions
(shown below each group). xN: sequencemultiplicity in each round. Among these putative interaction sites, once the energy of the folded configuration is
considered (Table S2) the only robust and energetically favoured interaction is that with the poly(A) apical loop.
www.nature.com/scientificreports
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RNApt16 was computationally challenging. In order to do so, we
extensively folded all sequences 59-CCCCNNNNNNNNGGGG-39
using RNAfold and kept those which had as theirMFE the stem-loop
structure 59-((((........))))-39. Out of 48 5 65,536 sequences of length
16 nt, 19,087 folded into the desired structure. For each of these
sequences, we compared the frame of 8 unpaired, variable nucleo-
tides in the trial molecules with a moving frame of 8 nucleotides along
the target RNA. We investigated the possible antiparallel interactions
(59-39 for the target UTR308 and 39-59 for negative control molecule).
For each trial sequence, there are 302 possible interaction positions
with the target. For each position of the moving frame, we counted: i)
the total number of bases compatible for pairing; ii) the number of
adjacent bases compatible for pairing. For each of the 19,087
sequences, we kept the maximum value of these two magnitudes
over 302 frame positions as the overall pairing number.
Since we were interested in sequences with the structure of
RNApt16, but binding the target with the lowest possible probability,
we first selected those sequences with minimum overall pairing num-
bers. As a result, we obtained 112 sequences which had: i) a max-
imum of 5 possible pairing events in an 8 nt-frame along the target
RNA; ii) a maximum of 4 possible adjacent pairs within the frame.
Using RNAup, we obtained for all these sequences their total inter-
action energies, taking into account the two individual structures. The
result showed interactions between 2 and 11 pairs of nucleotides and
total free interaction energies between 20.40 and 27.20 kcal/mol.
After analyzing the 112 sequences we chose as the negative con-
trol, termed RNApt16neg, the molecule 59-CCCCGAAAACAA-
GGGG-39 (Fig. 4D) which has the following properties: i) it is the
sequence of lowest total interaction energy with the target
(20.40 kcal/mol); ii) its interaction with the target is produced only
in 2 nt (positions 5–6 of RNApt16neg and positions 22–23 of the
target); iii) these interaction positions are in the loop of molecule
RNApt16neg.
In vitro testing of the aptamer binding to the HIV-1 UTR308
molecule. Binding to the HIV-1 target UTR308 was analyzed for
the two most abundant aptamers in populations XI and XIV (repre-
sented by sequences XIV22 and XIV26), and for RNApt16. Since
further inhibition assays were performed using fused aptamer-U6
snRNA cassette molecules, we carried out binding assays with these
chimeric molecules, termed LXIV22 and LXIV26. RNApt16 was
assayed without any modification for both binding and inhibitory
assays, as we were interested in studying the functional properties of
the minimal aptamer. The interaction of the RNApt16neg molecule
with the target was also assayed as a negative control. The binding
efficiency was analyzed by gel electrophoresis mobility shift assays
(Fig. 5). Multiple complex conformers were observed for the LXIV22
aptamer RNA, whereas amajor complex conformer was obtained for
LXIV26 (Fig. 5A) and RNApt16 aptamers (Fig. 5B). No interaction
was detected for the control molecule RNApt16neg, thus demon-
strating the usefulness of our in silico approach for designing such
a negative control. Results obtained from three independent
experiments were quantified and fitted to a hyperbolic one-site
binding curve with R2 coefficient higher than 0.99 for aptamers
LXIV26 and RNApt16, yielding a Kd of 82 6 13 nM and 280 6
60 nM, respectively. Binding of the aptamer LXIV22 responded to
a one-site specific binding curve with Hill slope, also with R2
coefficient higher than 0.99 and with a Kd of 154 6 5 nM.
Efficient inhibition of viral particle production by the selected
aptamers. The effect of the two most represented in vitro selected
aptamers, XIV22 and XIV26, on HIV-1 production was assayed.
Unmodified, pre-synthesized aptamers gave no satisfactory results
(data not shown), probably due to their limited half-life or incorrect
cellular location. Thus, we decided to flank them with the 59 and 39
stable hairpin-loop domains of the human U6 snRNA33 (Fig. 6A),
thus giving rise to the modified aptamers termed LXIV22 and
LXIV26. Aptamer sequences were cloned into vector pU614 and
templates for in vitro transcription of aptamers LXIV22 or LXIV26
were prepared from the resulting plasmids. HEK 293T cells were co-
transfected with 500 ng of in vitro transcribed LXIV22 or LXIV26
RNAmolecules and 100 ng of plasmid pNL4.3 (containing the HIV-
1 NL4.3 proviral DNA). Viral particle production was measured as
p24 antigen abundance in the cellular supernatant, yielding
inhibitions of 77 6 7% and 80 6 3%, respectively, in the HIV-1
viral particle production with respect to the control RNA termed
‘L-empty’, that was transcribed from a pU6 plasmid without any
cloned aptamer sequence, thus consisting in the two flanking U6
terminal 59- and 39-hairpins (Fig. 6B).
To validate the in silico shortening of the in vitro selected apta-
mers, inhibition of HIV-1 production by the designed RNApt16 was
also tested. HEK 293T cells were co-transfected with 500 ng of chem-
ically synthesized RNApt16 and 100 ng of pNL4.3. Inhibition of viral
particles production of 85 6 5% with respect to the synthetic
RNApt16neg control molecule, which did not showed inhibitory
effect, was observed (Fig. 6C). This result clearly points to the useful-
ness of the combined in vitro - in silico approach to design and
optimize novel anti-HIV-1 agents.
Discussion
Anti-HIV-1 RNA aptamers have been described to inhibit viral rep-
lication by interacting with different viral or cellular targets34–37. In
the present work, 64 nt-long RNA aptamers directed against the first
Figure 4 | In silico prediction of the MFE secondary structure of the
aptamers. (A) Group 2. (B) Group 1. (C) Rest of structures. (D) RNApt16
and RNApt16neg. _N: number of repetitions of a particular sequence. The
16 nt-long stem-loop motif is boxed. Probabilities for every nucleotide to
actually hold the structural position shown are represented by a colour
code from deep blue (lowest) to red (highest).
www.nature.com/scientificreports
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308 nt of the 59-UTR of the HIV-1 genomic RNA have been selected
in vitro. Based on our experimental results and on previous reports
on the computational study of the SELEX outcome30,35, we have
analysed in silico the RNA sequences and structures obtained along
the process. Interestingly, a conserved, 16 nt-long sequence-structure
motif present in most of the aptamers that target the viral RNA has
been identified. The in silico designed RNApt16 aptamer showed a
specific binding to the UTR308 RNA in vitro, and it efficiently inhib-
ited the production of HIV-1 viral particles in transient transfection
ofHEK293T cell cultures. To our knowledge, this RNApt16molecule
is the shortest anti-HIV-1 efficient aptamer described to date.
Actually, conventional SELEX procedures impose a minimal length
to the selected molecules and to the minimal aptamers obtained by
sequence trimming12,38,39, thus compromising the exploitation of
aptamers as therapeutic agents. This limitation is here overcome
by means of a combined in vitro – in silico approach.
The 16 nt-long, highly conserved stem-loop motif shared by most
of the selected aptamers (in particular, the abundant sequences
represented by XIV22 and XIV26) served as a guide for designing
the RNApt16 molecule, together with RNApt16neg as a negative
control. Binding of the RNApt16 molecule to the HIV-1 59-UTR
resembled the XIV26 binding behaviour with a single aptamer:target
complex and fitting to a hyperbolic binding curve, while XIV22
showed different aptamer:target complexes and a sigmoidal binding
curve. However, RNApt16 produced a less efficient binding with
respect to that of aptamers XIV22 and XIV26, evidencing a contri-
bution to the overall binding of the rest of the complete aptamer
molecules apart from their 16 nt-long motif.
There are several quantitative properties that characterize the
higher complexity of the selected, full-length aptamers in compar-
ison to RNApt16. The analysis of the ensemble diversity (ED) and the
frequency of the minimum free energy (FME) structure showed that
two groups of aptamers were segregated from round IX on, with each
of the two most represented molecules in round XIV belonging to
one of these subpopulations (Figs. S1 and S5). The subpopulation
represented by aptamer XIV26 (group 1) had low ED (3.12) and high
FME (33.22%), while that represented by XIV22 (group 2) showed
the opposite behaviour (ED 5 11.65; FME 5 6.07%). This obser-
vation eventually stems from the difference in stability of the two
corresponding folded configurations (Table S1, Figs. 4A, 4B and S8).
It is plausible that the structural plasticity of aptamer XIV22, with a
fold of low stability outside the conserved, relevant interaction site,
may promote multiple binding complexes, whereas aptamer XIV26
exhibits a robust secondary structure that likely entails a predom-
inant binding complex. This possibility is in agreement with the in
vitro results of the aptamer binding to the HIV-1 UTR308 molecule,
where the participation of extra regions present in aptamer XIV22
might be responsible for the formation of multiple aptamer:target
complexes and a binding curve with different topology with respect
to that of XIV26 and RNApt16 (Fig. 5). Nonetheless, the dominant
aptamer-target interaction is always that occurring at the consensus
octamer 59-GGCAAGGA-39, located at the apical loop of a structural
motif 59-((((........))))-39 within the aptamer. It is interesting that the
observation of other potentially binding regions is conditional on the
folded structure of the aptamer. Such is the case of region (a9) in Fig. 1
(see also Table S2), which interacts with a hexamer found in all
Figure 5 | Aptamers binding to the 59-UTR of HIV-1. Autoradiograms of representative native polyacrylamide gels resolving binding assays of LXIV22
and LXIV26 (A), RNApt16 and RNApt16neg (B), to the UTR308. .: unbound aptamer.c: aptamer-target complexes. Mean values of three independent
experiments are represented on the right.
www.nature.com/scientificreports
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assayed aptamers, since it belongs to the 39 common flanking region
(nucleotides 55–60): while in XIV22 and XIV1 that interaction is
observed, and it occurs with a relatively high binding energy, we have
not found it in XIV26. This observation is compatible with a dynamic
(low folding energy) configuration in nucleotides 55–60 of the for-
mer two aptamers (Fig. 4A), while in the latter the breakage of the
highly stable stem (Fig. 4B) followed by the binding to region (a9) is
not favoured energetically and does not take place. In agreement with
this result, we have checked that aptamer XIV5, characterized by a
significantly lower folding energy in that domain,may indeed bind to
(a9) (data not shown).
The HIV-1 inhibition efficiency of the aptamers seems to decrease
when different competing interaction sites are present in the mole-
cule, thus constituting an additional advantage of RNApt16. As a
matter of fact, while RNApt16 alone inhibits the production of viral
particles up to 85%, inhibition by the in vitro selected 64 nt-long
aptamers was only produced (up to 75%) when fused to the U6
snRNA flanking hairpins (Fig. 6 and data not shown) that increase
their molecular length inmore than 60 nt. Indeed, we cannot discard
that the addition of the flanking hairpins had a direct effect on the
aptamer-target interaction.
The preferred target site of the selected aptamers and the RNApt16
molecule was the 59-CUUGCC-39 sequence (nts 81–86 of the HIV-1
genome) exposed in the apical loop of the essential poly(A) domain
(Fig. 1). This hexamer is highly conserved among all the HIV-1
strains, subtypes, circulating intersubtype recombinant forms and
groups, and even among the closely related simian immunodefi-
ciency virus (SIV) from chimpanzee40,41 (Fig. S9 and data not shown).
This sequence conservation makes interesting to analyze the inhib-
itory potential of the selected aptamers and RNApt16 against differ-
ent clinical HIV-1 isolates belonging to distinct viral subtypes and
groups. Although an identical poly(A) domain is present at both ends
of all intracellular genomic and subgenomic HIV-1 RNAs, only the
poly(A) at the 39 end leads to polyadenylation of the HIV RNAs42.
Therefore, we hypothesize that the achieved inhibitory effect of the in
vitro selected aptamers and the in silico derived one (RNApt16)
might be explained as a result of the interference with the proper
39 end RNA polyadenylation (Fig. 7).
However, we cannot discard other inhibitory effects derived from
aptamer binding to the 59 poly(A) domain. The binding of the apta-
mers to the 59 end poly(A) domain might additionally interfere with
translation, reverse transcription, RNA dimerisation and encapsida-
tion, by affecting the folding of neighbouring domains within the
59UTR9,43–45. The interference with the later two processes may result
in the promotion of aberrant genomic-subgenomic RNA heterodi-
mers through 59-UTR reshape, yielding viral particles that are
incompetent for infection (Fig. 7). Additionally, aptamer binding
might interfere with the previously described pseudoknot involving
the 59 poly(A)-targeted nucleotides and a downstream gag ORF
region, whose function remains unknown46. In any case, we provide
evidences that interfering with the poly(A) domain may effectively
challenge the successful completion of the HIV-1 cycle.
Our results underline the usefulness of the engineered RNApt16
aptamer as an active inhibitor of HIV-1. RNApt16 includes a 4 bp-
long stem entirely composed of G-C pairs that could protect the
molecule against 59-end degradation, as U6 snRNA hairpins may
do in LXIV22 and LXIV26 aptamers. Indeed, uncapped and unpo-
lyadenylated natural RNAs protect from exonucleases degradation
by trapping their ends into G-C rich hairpins (e.g. naked RNA
viruses, tRNAs and 5S rRNA38,39,47 and such a protection is usually
Figure 6 | Ex vivo HIV-1 inhibition assays. (A) Schematic representation of the U6-aptamer RNA constructs. (B) Inhibition of HIV-1 p24 antigen
production by LXIV22 and LXIV26, using ‘L-empty’ as control. (C) Inhibition by RNApt16 and RNApt16neg. Data represent the mean of three
independent experiments. **: statistically significant differences as compared to the control (ANOVA, p , 0.01).
www.nature.com/scientificreports
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essential to increase the half-life and, thus, the efficiency of inhibitory
RNAs for therapeutic applications24,48,49. The remarkably small size of
RNApt16 and its clear inhibitory effect without the need of further
modificationsmakes of this poly(A) domain-bindingmolecule a very
promising candidate for the development of anti-HIV strategies. A
putative increase of the stability of either the in vitro selected apta-
mers or the in silico designed one will be explored by chemical mod-
ifications. Finally, the eventual selection of resistance mutations to
the reported aptamers will be subject of further investigation. In any
case, the combination of RNApt16 with other aptamers or with
distinct inhibitory RNA molecules (e.g. siRNAs) of different specifi-
city might help delaying the generation of escape HIV-1 mutant
variants, as it has already been shown in mouse models50.
Altogether, our results exemplify the applicability of an in vitro - in
silico combined approach for the design and optimization of efficient
anti-HIV-1 aptamers, useful as either drug candidates or diagnostic
tools.
Methods
DNA templates and RNA synthesis. The HIV-1 59-UTR RNA target molecule
(termed UTR308 since it spans the first 308 nts of the genomic sequence) was
synthesized by in vitro transcription of a PCR-amplified DNA template obtained
from the pNL4.3 plasmid as previously described51. In turn, the pU6-based eukaryotic
RNA expression vectors were obtained by cloning the aptamer coding sequences
XIV22 and XIV26 within the KpnI and ApaI restriction sites of vector pU614. The
aptamer-coding fragments were obtained by PCR amplification of the corresponding
pGEM-THeasy (Promega, Madison, US-WI) aptamer-coding plasmid, using primers
59KpnIC3 (59-CGACTCGGTACCGGGAATTCAA-39) and 39ApaIC3 (59-
TCTGGGCCCGTCGAGCTCGTAGTATC-39). The resulting plasmids were called
pU6-LXIV22 and pU6-LXIV26, and led to the synthesis of the 128 nt-long LXIV22
and LXIV26 RNA molecules, composed of the corresponding RNA aptamer flanked
by the 59 and 39 hairpins of the human U6 snRNA. RNA molecules LXIV22 and
LXIV26 were obtained by in vitro transcription of the corresponding PCR templates
as previously described51.
In vitro selection of aptamers. RNA aptamers were generated using a SELEX
procedure against the HIV-1 molecule UTR308. The starting population of 84 nt-long
DNAmolecules consisted of 25 randomized nts flanked by constant sequences, and it
was obtained by annealing and extension of 7.5 nmol of each of the oligonucleotides
59EcoRIK (59-GGATAATACGACTCACTATAGGGAATTCAA-39) and
39RANDOMK (59-GTCGAGCTCGTAGTATCAGATCACTCCATN25TTG-
AATTCCCTATAGTG-39), where the underlined sequence corresponds to the T7
RNA polymerase promoter and ‘N’ stands for a randomized position. The amount of
the oligonucleotide including the 25 nt-long random region was 4-fold higher than
the theoretical number of different molecules (1.1 3 1015). The population of 64 nt-
long RNA aptamers was in vitro transcribed as previously described52.
The target RNAmolecule UTR308 was internally biotinylated during transcription
by adding biotinylated-UTP (Roche, Indianapolis, US-IN) to the transcriptionmix at
0.106 mM final concentration (in the presence of 1 mMnon-biotinylated UTP). This
rendered the incorporation of, on average, one biotinylated-UTP residue per mole-
cule. Two transcription reactions were performed in parallel at 37uC for 2 hours, and
DNA templates were removed using RQ1 DNase (Promega, Madison, US-MA) at
1 U/mg DNA concentration, at 37uC for 30 min. All transcription products were gel-
purified and ethanol-precipitated.
The target RNA was resuspended in 1 ml of binding buffer (150 mM sodium
chloride, 20 mM sodium phosphate, pH 7.5) and renatured at 65uC for 10 min
followed by an additional incubation at 37uC for 10 min. Then, biotinylated UTR308
was bound to a HiTrapTM Streptavidin HP column (GE Healthcare, Chalfont ST.
Giles, UK) following manufacturer’s instructions. The column was washed with
10 ml of binding buffer and equilibrated with 10 ml of TMN 13 buffer (20 mM
TRIS-acetate; 10 mM magnesium acetate; 100 mM sodium chloride). The starting
RNA aptamer population exceeded 40 mg weight, theoretically ensuring the presence
of at least one copy of each of the possible sequence variants. Previous to the first
selection round, a negative selection step was carried out to prevent selection of
sepharose and/or streptavidin-binder molecules: for this purpose the initial RNA
population was passed through an unloaded-sepharose column at 25uC and the
unbound molecules were recovered. This RNA population was loaded into a target-
Figure 7 | Model of putative functional effects of RNApt16 binding to poly(A) domain. UTR308 region in genomic (A) and subgenomic (B) RNAs is
shown in black. The RNApt16 is shown in red. Poly(A)-gag pseudoknot is represented by a gray line in (A). The arrowhead points the major splicing
donor.
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containing column in 1 ml of TMN 13, and incubated for binding at 25uC for
30 min. Unbound molecules were discarded by washing with 10 ml of TMN 13 at
the binding temperature, and boundmolecules were further recovered by elutionwith
10 ml of TMN 13 at 95uC. The first four 1 ml fractions recovered were concentrated
using Centricon Ultracel YM-3 (Merck Millipore, Billerica, US-MA), and ethanol-
precipitated.
One half of the recovered RNA pool was reverse transcribed and amplified by Tth
DNA polymerase (Promega, Madison, US-WI) using the primers 39XhoIK (59-
GTCGAGCTCGTAGTATCAGATCACTCCAT-39) and 59EcoRIK. The cDNA
populationwas phenol-extracted, ethanol-precipitated and used as template for a new
round of selection. Fourteen rounds of amplification-selection were performed, and
the selection pressure was increased along the procedure as follows: i) binding tem-
perature was 25uC for the rounds I to III, and 37uC for the rounds IV to XIV; ii) the
aptamer:target ratio was 151 for the rounds I to X, and 100051 for the rounds XI to
XIV. The second half of the cDNA population of each round was cloned in E. coli
using pGEM-THeasy vector, and a minimum of 24 molecular clones were sequenced.
In silico methods for sequence analysis. For sequence comparison, Hamming
distances between each pair of clonal sequences were calculated as the number of
positions at which the corresponding nucleotides are different. Clustering of the non-
repeated, 64 nt-long sequences was performed based on their mutual Hamming
distances. An outgroup sequence was designed that contained the 10 nt and 29 nt-
long constant sequences present at the 59 and 39 ends of all molecules, flanking an
artificial 25 nt-long sequence 59-(ACGT)6A-39. Thus, the complete sequence of the
outgroup was: 59-GGGAATTCAAACGTACGTACGTACGTACGTACGTAA-
TGGAGTGATCTGATACTACGAGCTCGAC-39. The topology of the clustering
was inferred by means of the neighbour-joining (NJ) method53 using the program
NEIGHBOR from the PHYLIP v3.6 package54.
In silicomethods for analyzing RNA structure.Weused theVienna RNApackage55,
version 1.5, to fold RNA sequences into their minimum free energy (MFE) secondary
structure, as well as to compare the obtained structures (see below). The previously
described standard parameter set56 was used, allowing for A-U, G-C, and wobble G-U
base pairs, and disallowing the formation of isolated base pairs. Three relevant
quantities were computed for every folded structure, in addition to its folding energy:
i) its ensemble diversity (ED); ii) the frequency of the MFE structure (FME) in the
thermodynamic ensemble; iii) the ensemble centroid structure (CE). The ED is the
average distance between all the possible secondary structures present in the
thermodynamic ensemble, which is in turn defined as the set of all different structures
(each characterized by its corresponding folding energy) compatible with a given
sequence. Structures with similar energy in the ensemble are found with comparable
frequency. If the energy of the MFE structure is significantly lower than the rest of
structures in the ensemble, then the corresponding sequence will foldmost of the time
in the MFE structure, and it will thus be much more frequent. The centroid of a set of
structures is the structure that has the minimum total base-pair distance to the
structures in the set, thus being the single structure that best represents the set as a
whole57. For representation of RNA secondary structures the dot-bracket notation
was used, where unpaired nucleotides are denoted by dots, and paired nucleotides by
parentheses: ‘(’ indicates that the partner is downstream, and ‘)’ that the partner is
upstream.
Structure comparison was performed by means of base-pair distances, which
measure the number of base pairs that must be opened and closed in order to convert
one structure into the other. We checked that structure comparison through
Hamming or tree-edit distances yielded qualitatively equivalent results. The
Hamming distance between two folded sequences (that must be of equal length) is
defined as the number of positions at which the structural states [‘.’, ‘(‘ or ‘)’] of the
corresponding nucleotides differ. In turn, the tree–edit distance compares structural
elements (e.g., hairpins, bulges or stems) and allows for a variable number of
nucleotides involved in those motifs or separating them. It is slightly more compu-
tationally complex since it was devised to compare sequences of different length58.
A cluster analysis of the structures was performed, based on their base-pair dis-
tances. An artificial outgroup structure was designed, showing themaximum number
of paired bases in their 64 nt-long sequence: 59-((((((((((((((((((((((((((((((....))))))))))-
))))))))))))))))))))-39. Clustering was performed as described above.
To predict those sites where interaction between aptamer and ligand is favoured,
we used the RNAup algorithm from the Vienna RNA package, version 1.8.459. RNA-
RNA binding is decomposed in two steps: first, the probability that a sequence
interval (e.g. a binding site) remains unpaired is computed; in a second step, the
binding energy provided that the binding site is unpaired is calculated as the optimum
over all possible types of bindings60. Parameters are chosen as for RNAfold. In par-
ticular, isolated base pairs are not allowed and the length of the unstructured regions
is 4 nts.
In vitro aptamer binding assays. The evaluation of the binding efficiency of the
selected aptamers was essentially performed as previously described32, using trace
amounts of renatured, 59 end 32P-labelled aptamers and 0, 2, 20, 200 or 400 nM of
non-labelled UTR308 target RNA.
Results obtained from three independent experiments were quantified and fitted to
either a hyperbolic one-site binding curve (Equation 1) or a one-site specific binding
curve with Hill slope (Equation 2):
Y~Bmax:X=(KdzX) ð1Þ
Y~Bmax:X
h=(Kd
hzXh) ð2Þ
where Bmax is the maximum value of Y (when X 5 ‘); Kd is the value of X when Y 5
Bmax/2; and h is the Hill slope and indicates the degree of cooperativity.
HIV-1 inhibition assays. The viral production inhibition assays were performed by
transient transfection of human embryonic kidney (HEK) cells as previously
described51, using 100 ng of plasmid pNL4.3 plus 500 ng of RNA aptamer in co-
transfection experiments14.
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